Abomin

 Abomin

Abomin is a combined preparation comprising proteolytic enzymes which act on the food (mainly milk) proteins while retaining their activity under neutral and slightly acidic medium. Get a raw material for the manufacture of a medicament of the gastric mucosa of lambs and calves.

Using abomin improves the digestion process in the case of low enzyme activity of gastric juice.

Release form and composition

According to the group affiliation, abomin refers to digestive enzyme means. The main active ingredient of the drug are rennet, and as auxiliaries used potato starch and calcium stearate.

The drug is made by several Russian pharmaceutical companies:

  • Moscow factory of rennet;
  • St. Petersburg STRINGS antibiotics and enzymes for medical purposes;
  • Moshimfarmpreparaty FSUE them. Semashko;
  • State Research Institute of Standardization and Control of Drugs MZ Russia.

Rennet is a yellowish-gray powder having a salty taste and a characteristic odor. Their activity is determined by the biological method. Since 1 g contains 250 000 IU., Molokostvorazhivayuschaya the enzyme activity contained in one tablet (200 mg) abomin, corresponding to 50 000 units.

Available in the form of the medication:

  • Powder;
  • Tablets for adults (50 000 units);
  • Tablets for children (10 000 units).

Tablets lenticular shape, color from light yellow to yellow-gray. On the surface, allowed the inhomogeneous distribution of inclusions of varying intensity. There is a faint specific odor, characteristic of rennet.

Indications

According to the instructions abomin, the drug should be used in diseases of the gastrointestinal tract, which is characterized by a violation of the digestive capacity and reduced gastric acidity. It:

  • Gastritis;
  • Enterocolitis;
  • Gastroenteritis;
  • Achilios;
  • Status after resection of the stomach;
  • Dyspepsia.

There was also a positive clinical experience in the treatment of intestinal dysbiosis abomin drug in children.

Contraindications

Application abomin contraindicated for persons suffering obstruction of the gastrointestinal tract, as well as having an increased sensitivity to the drug.

Do not prescribe medicine to infants who have seen the syndrome of regurgitation and vomiting.

Dosage and Administration

Adults and children over 14 years abomin should be taken 3 times a day 1 tablet with meals. The course of treatment is 1-2 months, however, if the desired effect is not observed, the single dose should be increased to 3 tablets, and treatment extended to 3 months.

Acute gastritis, gastroenteritis and colitis, according to the instructions abomin are testimony to the acceptance of the drug three times a day 1 tablet for 2-3 days.

For children, the medicament is assigned as follows:

  • 10-14 years - 3 tablets children (10 000 units.) Per day;
  • 6-9 years - 2 tablets children;
  • 2-5 years - 1 tablet child;
  • Up to a year - on 0, 5 children's tablets.

The course of treatment for children abomin is from 1 to 3 months, depending on the diagnosis and efficacy of treatment.

Side effects

The instructions to abomin said that the side effects of this drug are shown in the form of nausea and heartburn.

Typically, the drug is well tolerated, but the possible negative effects of abomin should still be considered when appointing his children younger age group who are not yet able to warn arisen discomfort.

Cautions

Not found cases of drug overdose, and no evidence of drug interactions.

Not surveyed abomin use during lactation and pregnancy.

Analogs

Close abomin mechanism influence drugs that belong to the same pharmacological subgroup: bios, Biofestal, Vestal, Gastenorm, Creon, Mezim, Mikrazim, Nigedaza, Normoenzim, Orazov granules Panzica, Panzi, Panzinorm, Pankreazim, pancreatin Pankrenorm, Pankreoflat, pantsitrat , Penzital, Pepsin K Pepfiz, Top-Festal, Ferestal, Festal, enzistal, Enterosan, Ermital, Yunienzim, Pangrol.

Terms and conditions of storage

Keep abomin should be in a dark, dry place at a temperature of 15-25 ° C.

Shelf life is 2 years. The date after which the drug is considered to be unfit, specified by the manufacturer on the packaging.





Яндекс.Метрика